| Ytd | 2.35% | |
| 1y | -35.00% |
| Open | 0.79 | Prev Close | 0.77 | Low | 0.74 | High | 0.79 | Mkt Cap | 7.96M |
| Vol | 60.09K | Avg Vol | 182.33K | EPS | -0.89 | P/E | N/A | Forward P/E | -4.21 |
| Beta | -0.20 | Short Ratio | 1.09 | Inst. Own | 13.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.77 | 200-d Avg | 0.82 | 1yr Est | 0.00 |
PMCB News
On December 1, 2025, PharmaCyte Biotech, Inc. (the "Company") received a written notice (th
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announ
PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly losses of $(1.23) per share. This is a 164.74 pe
TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recog
PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly earnings of $1.54 per share. This is a 566.67 pe
Second external investment in life sciences solidifies previously announced strategy to utilize sign
New investment marks expansion of corporate strategy to utilize significant cash position to create
Company prepares for comprehensive discussion with FDA to determine appropriate next steps for techn
On Monday, 369 companies set new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June
Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 pe
LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte
https://pharmacyte.com/pharmacyte-biotech-rebukes-iroquois-commencement-of-consent-solicitation/
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular thera
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular thera
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) (PharmaCyte), a biotechnology company focused on developing c
roquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the large
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Incr
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program PharmaCyte Biotech, Inc. (NASD
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular thera
Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Val
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular thera
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular thera
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular thera
Gainers
Gainers
Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Thursday
Stocks That Hit 52-Week Lows On Wednesday